Onconetix (ONCO) Exchange Rate Effect (2024 - 2026)
Onconetix (ONCO) posted quarterly Exchange Rate Effect of -$14889.0 for Q1 2026, down 124.77% year-over-year from $60119.0 in Q1 2025, and down 101.6% quarter-over-quarter from $927975.0 in Q4 2025.
Onconetix (ONCO) Exchange Rate Effect (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Exchange Rate Effect for 3 consecutive years, with -$14889.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 124.77% year-over-year to -$14889.0; the TTM figure through Mar 2026 stood at -$275150.0 (down 3509.94% YoY), while the FY2025 annual figure was -$200142.0, down 58.02% from the prior year.
- Exchange Rate Effect slipped to -$14889.0 in Q1 2026 per ONCO's latest filing, from $927975.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $927975.0 in Q4 2025 and bottomed at -$627956.0 in Q2 2025.
- Historically, Exchange Rate Effect has averaged -$37965.4 across 3 years, with a median of -$18798.0 in 2024.
- On a YoY basis, Exchange Rate Effect climbed as much as 1316.63% in 2025 and fell as far as 2880.53% in 2025.
- Onconetix's Exchange Rate Effect stood at -$76274.0 in 2024, then jumped by 1316.63% to $927975.0 in 2025, then plunged by 101.6% to -$14889.0 in 2026.
- Business Quant data shows ONCO's Exchange Rate Effect at -$14889.0 in Q1 2026, $927975.0 in Q4 2025, and -$560280.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -24,131.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24,131.00 |
| Jun 30, 2026 | -24,131.00 |
| Mar 31, 2026 | -14,889.00 |
| Mar 31, 2026 | -14,889.00 |
| Dec 31, 2025 | 927,975.00 |
| Dec 31, 2025 | 927,975.00 |
| Sep 30, 2025 | -560,280.00 |
| Sep 30, 2025 | -560,280.00 |
| Jun 30, 2025 | -627,956.00 |
| Jun 30, 2025 | -627,956.00 |
| Mar 31, 2025 | 60,119.00 |
| Mar 31, 2025 | 60,119.00 |
| Dec 31, 2024 | -76,274.00 |
| Dec 31, 2024 | -76,274.00 |
| Sep 30, 2024 | -18,798.00 |
| Sep 30, 2024 | -18,798.00 |
| Jun 30, 2024 | 27,331.00 |
| Jun 30, 2024 | 27,331.00 |
| Mar 31, 2024 | -58,917.00 |
| Mar 31, 2024 | -58,917.00 |